We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed at $15.14, marking a +0.93% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Meanwhile, the Dow lost 0.51%, and the Nasdaq, a tech-heavy index, added 0.21%.
Prior to today's trading, shares of the company had lost 6.25% over the past month. This has lagged the Medical sector's loss of 5.37% and the S&P 500's gain of 4.65% in that time.
Wall Street will be looking for positivity from TEVA as it approaches its next earnings report date. This is expected to be May 2, 2019. In that report, analysts expect TEVA to post earnings of $0.58 per share. This would mark a year-over-year decline of 38.3%. Our most recent consensus estimate is calling for quarterly revenue of $4.43 billion, down 12.46% from the year-ago period.
TEVA's full-year Zacks Consensus Estimates are calling for earnings of $2.39 per share and revenue of $17.28 billion. These results would represent year-over-year changes of -18.15% and -8.33%, respectively.
Investors might also notice recent changes to analyst estimates for TEVA. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.16% lower within the past month. TEVA currently has a Zacks Rank of #5 (Strong Sell).
In terms of valuation, TEVA is currently trading at a Forward P/E ratio of 6.29. For comparison, its industry has an average Forward P/E of 6.92, which means TEVA is trading at a discount to the group.
It is also worth noting that TEVA currently has a PEG ratio of 2.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA's industry had an average PEG ratio of 1.11 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed at $15.14, marking a +0.93% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Meanwhile, the Dow lost 0.51%, and the Nasdaq, a tech-heavy index, added 0.21%.
Prior to today's trading, shares of the company had lost 6.25% over the past month. This has lagged the Medical sector's loss of 5.37% and the S&P 500's gain of 4.65% in that time.
Wall Street will be looking for positivity from TEVA as it approaches its next earnings report date. This is expected to be May 2, 2019. In that report, analysts expect TEVA to post earnings of $0.58 per share. This would mark a year-over-year decline of 38.3%. Our most recent consensus estimate is calling for quarterly revenue of $4.43 billion, down 12.46% from the year-ago period.
TEVA's full-year Zacks Consensus Estimates are calling for earnings of $2.39 per share and revenue of $17.28 billion. These results would represent year-over-year changes of -18.15% and -8.33%, respectively.
Investors might also notice recent changes to analyst estimates for TEVA. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.16% lower within the past month. TEVA currently has a Zacks Rank of #5 (Strong Sell).
In terms of valuation, TEVA is currently trading at a Forward P/E ratio of 6.29. For comparison, its industry has an average Forward P/E of 6.92, which means TEVA is trading at a discount to the group.
It is also worth noting that TEVA currently has a PEG ratio of 2.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA's industry had an average PEG ratio of 1.11 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 163, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.